## Pretomanid (pretomanid) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

**Instructions:** Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

MEMBER INFORMATION				
LAST NAME:	FIRST NAME:			
PHONE NUMBER:	DATE OF BIRTH:			
STREET ADDRESS:				
CITY:	STATE: ZIP CODE:			
PATIENT INSURANCE ID NUMBER:				
MALE FEMALE HEIGHT (IN/CM): WEIGHT (LB/KG): ALLERGIES:				
IF YOU ARE NOT THE PATIENT OR THE PRESCRIBER, YOU WILL NEED TO SUBMIT A PHI DISCLOSURE AUTHORIZATION FORM WITH THIS REQUEST WHICH CAN BE FOUND AT THE FOLLOWING LINK: PRIMETHERAPEUTICS.COM/NOPP				
PATIENT'S AUTHORIZED REPRESENTATIVE (IF APPLICABLE):				
AUTHORIZED REPRESENTATIVE'S PHONE NUMBER:				

PRESCRIBER INFORMATION				
LAST NAME:	FIRST NAME:			
PRESCRIBER SPECIALTY:	EMAIL ADDRESS:			
NPI NUMBER:	DEA NUMBER:			
PHONE NUMBER:	FAX NUMBER:			
STREET ADDRESS:				
CITY:	STATE: ZIP CODE:			
REQUESTOR (if different than prescriber):	OFFICE CONTACT PERSON:			

MEDICATION OR MEDICAL DISPENSING INFORMATION					
MEDICATION NAME:					
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILLS:	QUANTITY:		
NEW THERAPY	RENEWAL	IF RENEWAL: DATE THERAPY INITIATED:			
DURATION OF THERAPY (SPECIFIC DATES):					

Continued on next page.



URGENT

## Pretomanid (pretomanid) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST NAME:			
1. HAS THE PATIENT TRIED ANY OTHER	R MEDICATIONS FOR THIS CONDITION?	YES (if yes, complete below) 📃 NO		
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):	<b>DURATION OF THERAPY</b> (SPECIFY DATES):	RESPONSE/REASON FOR FAILURE/ALLERGY:		
2. LIST DIAGNOSES:		ICD-10:		
<ul> <li>Extensively drug resistant tuberculosis (XDR-TB)</li> <li>Multi-drug resistant tuberculosis (MDR-TB)</li> </ul>				
Other diagnosis:	ICD-10:			
<b>3. REQUIRED CLINICAL INFORMATION:</b> PLEASE PROVIDE ALL RELEVANT CLINICAL INFORMATION TO SUPPORT A PRIOR AUTHORIZATION. <b>Clinical Information:</b>				
Has the patient been non-responsive to isoniazid, rifamycins (such as rifampin), a fluoroquinolone (such as levofloxacin) AND an injectable (such as amikacin)? <ul> <li>Yes</li> <li>No</li> <li>Please submit documentation</li> </ul>				
Has the patient been non-responsive to the best available regimen for at least 6 months? <ul> <li>Yes</li> <li>No</li> </ul>				
Is the patient inolerant of ANY of the following?: Para-amino salicylic acid, ethionamide, aminoglycosides (such as amikacin), or fluoroquinolones (such as levofloxacin)  u Yes  u No <i>Please submit documentation</i>				
Is the prescriber an infectious disease	specialist? 🗆 Yes 🗆 No			
Has the patient had a chest x-ray cons	istent with pulmonary TB? 🛛 Yes 🗆 No	Please submit documentation		
Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?				
*Please note: Not all drugs/diagnoses are covered on all plans. This request may be denied unless all required information is received.				
<b>ATTESTATION:</b> I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical				
information necessary to verify the accuracy of the information reported on this form.				
Prescriber Signature or Electronic I.D.		Date:		
you are not the intended recipient, you are here	ompanying this transmission contain confidential by notified that any disclosure, copying, distribut have received this information in error, please no se documents.	tion, or action taken in reliance on the contents		
FAX THIS FORM TO: 800-424-7640				
MAIL REQUESTS TO:	Prime Therapeutics Management Prior A Attn: CP – 4201 P.O. Box 64811 St. Paul, MN 55164-0811	Authorization Program		
	·			

© 2017–2024 Prime Therapeutics Management LLC, a Prime Therapeutics LLC company Revision Date: 08/22/2018 CAT0295 2/1/2020